TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03339765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Together serious game
Description: The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
Study: NCT03012880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01584297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
Study: NCT04189783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02268305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSM 1000mg twice a day (6000 mgs)
Description: MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules twice a day
Description: Placebo is a capsule filled with rice flour.
Study: NCT03288584

Intervention type: DRUG
Intervention: Corticosteroid and non-biological agents.
Description: Enhanced treatment with corticosteroid and non-biological agents.
Study: NCT02571179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl 50 microg dose up to 250 microg
Description: When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
Study: NCT00934531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline.
Study: NCT03686202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-4
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-4
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-4
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-4
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
Study: NCT00908908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
Study: NCT03141307

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EICI Movie
Description: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EICI App
Description: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of care, paper-based brochure
Study: NCT03406949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: obrindatamab
Description: B7-H3 x CD3 DART protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: anti-PD-1 antibody
Study: NCT04791397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
Description: Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
Study: NCT03584308

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glizigen Placebo
Description: The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
Study: NCT04065646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile
Study: NCT04054258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App support Programme (ASP) group
Description: All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: App support Programme (ASP) group
Description: All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
Study: NCT03226613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcervical Oropharyngeal Ultrasound
Description: One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Rinse Collection
Description: Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
Study: NCT04791397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
Description: Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
Study: NCT02260414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: single subcutaneous injection of 4500 IU tinzaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: single subcutaneous injection of 4500 IU tinzaparin
Study: NCT02054468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.15mg/kg/body mass)
Description: Rocuronium (0.15mg/kg/body mass)
Study: NCT02260414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: single subcutaneous injection of 4500 IU tinzaparin
Study: NCT03012880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02994836

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TNF: Infliximab (Infusion)
Description: Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF discontinuation: Physiological saline solution
Description: Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TNF:Adalimumab (Subcutaneus)
Description: Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF discontinuation: Physiological saline solution
Description: Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
Study: NCT03565562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of the e-health tool by local authorities
Description: Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of the e-health tool by local authorities
Description: Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of the e-health tool by local authorities and GPs
Description: In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
Study: NCT01954030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO and Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO and Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO alone
Study: NCT03540979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial preparation for frozen blastocyst transfer
Description: medical endometrial preparation for frozen blastocyte transfer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial preparation for frozen blastocyst transfer
Description: medical endometrial preparation for frozen blastocyte transfer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitor - 2.5mg/d for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovidrel
Description: recommbinant hCG 250 mcg- single sc injection to induce ovulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrofem
Description: Estrofem 2mg\*3/d for endometrial preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin 100Mg Vaginal Insert
Description: vaginal tab for lutheal support
Study: NCT03021876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: treatment with oral L-carnitine, 1500 mg/body per day
Study: NCT01608308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: 1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
Study: NCT03401879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Nerve fiber layer thickness and central retinal thickness will be measured using OCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
Study: NCT02054468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.2mg/kg/body mass)
Description: Rocuronium (0.2mg/kg/body mass)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.2mg/kg/body mass)
Description: Rocuronium (0.2mg/kg/body mass)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.3mg/kg/body mass)
Description: Rocuronium (0.3mg/kg/body mass)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.3mg/kg/body mass)
Description: Rocuronium (0.3mg/kg/body mass)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.45mg/kg/body mass)
Description: Rocuronium (0.45mg/kg/body mass)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.45mg/kg/body mass)
Description: Rocuronium (0.45mg/kg/body mass)
Study: NCT02104973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
Study: NCT02285556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychological rehabilitation training
Description: The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical and neurological rehabilitation training
Description: The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: rTMS 10HZ high frequency stimulation
Description: Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: fake rTMS 10HZ high frequency stimulation
Description: Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
Study: NCT01742247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiogel
Description: Application of moisturizer on laser-treated area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Application of moisturizer on laser-treated area
Study: NCT03242824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorodopa
Description: Contrast used in PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: imaging test
Study: NCT03540979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin 100Mg Vaginal Insert
Description: vaginal tab for lutheal support
Study: NCT01155245

Intervention type: DRUG
Intervention: Forteo
Description: Forteo pen
Study: NCT04597918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
Study: NCT02112526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study: NCT02260414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
Study: NCT04707326

Intervention type: DRUG
Intervention: Dolutegravir / Lamivudine Pill
Description: HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
Study: NCT04534218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: * For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg per os, daily, for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m²/orally twice daily continuously for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75 mg orally and daily until progression